Pulmonary hypertension encompasses a range of conditions that lead through varying mechanisms to an elevated mean pulmonary artery pressure of ≥ 25 mmHg at right heart catheterization. This update on pulmonary hypertension management will focus on those areas in which major recent developments have occurred, specifically pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. An increasing repertoire of approved targeted medical therapies and data supporting the efficacy of combination therapy have transformed the management algorithm for pulmonary arterial hypertension, which has recently been updated in the 2015 European Society of Cardiology/European Respiratory Society guidelines. For patients with chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy remains the treatment of choice. However, treatment options for those with adjudicated inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension have expanded. Riociguat has demonstrated efficacy and is approved for these patients, and balloon pulmonary angioplasty is being offered at an increasing number of expert centres worldwide. (BRN Rev. 2016;2:114-28)
INTRODUCTION
Pulmonary hypertension (PH) is an abnormal haemodynamic state of the pulmonary circulation defined by an elevated resting mean pulmonary artery pressure (mPAP) of ≥ 25 mmHg at right heart catheterisation 1 . Pulmonary hypertension is further stratified as pre-capillary when the pulmonary artery wedge pressure (PAWP) is ≤ 15 mmHg or post-capillary when PAWP is > 15 mmHg 2 . Pulmonary hypertension can develop as the consequence of many distinct disease entities, and the current clinical classification divides PH into five separate subgroups based on shared pathophysiology, clinical features, and therapeutic approach (Table 1) 1, 3 .
Group 1 pulmonary arterial hypertension (PAH)
is comprised of a group of rare conditions where the primary abnormality is a vasculopathy affecting the distal pulmonary arteries 4 . Modern trials of "targeted" pulmonary vasodilator therapies have evaluated mainly patients with Group 1 PAH, where an increasing number of randomised controlled trial (RCT) data have been accumulated over the past two decades to support the efficacy of these agents in improving exercise capacity, quality of life, and clinical outcomes 4, 5 . Group 2 PH is dedicated to left heart disease where the elevation in mPAP is predominantly related to passive transmission of high left atrial pressure (i.e. post-capillary PH), although pulmonary arterial remodelling may develop as a consequence of long-standing pulmonary venous hypertension 6 . Group 3 PH comprises chronic lung diseases, sleep disordered breathing, alveolar hypoventilation syndromes, and chronic exposure to altitude. Group 4 PH is related to chronic thromboembolic disease, where persisting obstruction of pulmonary arteries occurs due to non-resolution and organization of chronic thrombi. Finally, Group 5 PH consists of miscellaneous conditions with unclear or multifactorial mechanisms leading to PH. This review will aim to provide a succinct but comprehensive update on the therapeutic approach to PH. For the purpose this review, we will focus on Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension (CTEPH), since major developments have occurred recently in the management of these conditions.
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is characterised by proliferative and fibrotic remodelling of the distal pulmonary arteries, resulting in 
Group 1'
Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
Group 1" Persistent pulmonary hypertension of the new-born

Group 2
Pulmonary hypertension due to left heart disease
Group 3
Pulmonary hypertension due to lung diseases and/or hypoxia
Group 4
Chronic thromboembolic pulmonary hypertension
Group 5
Pulmonary hypertension with unclear and/or multifactorial mechanisms ALK-1: activin receptor-like kinase 1; BMPR2: bone morphogenetic protein receptor type II; CAV1: caveolin-1; ENG: endoglin; KCNK3: potassium channel subfamily K member 3; SMAD9: mothers against decapentaplegic homolog 9.
vascular luminal obstruction and a progressive rise in pulmonary vascular resistance (PVR) 7, 8 . It remains a potentially fatal disease, with right ventricular failure being the main cause of death 9 , but targeted medical therapy in the current era has led to significant improvements in survival [10] [11] [12] . Pulmonary arterial hypertension is termed idiopathic when no aetiological factors are identified, but can also be heritable, drug and toxin-induced, or be associated with conditions such as connective tissue disease, congenital heart disease, HIV infection, and portal hypertension 13 . The diagnosis of PAH requires invasive haemodynamic confirmation of precapillary PH (mPAP ≥ 25 mmHg, PAWP ≤ 15 mmHg, and PVR > 3 Wood units) with the exclusion of left heart disease, lung disease, and chronic thromboembolism.
Dysfunction of the endothelium is a key process in the pathogenesis of PAH, although our current understanding suggests that the pathobiology is complex and involves predisposing factors such as inflammation and immune dysregulation, altered cross-talk between cells within the vascular wall, metabolic and mitochondrial abnormalities, abnormal growth factor stimulation and cell signalling, ion channel defects, and germline mutations 4, [14] [15] [16] [17] [18] [19] [20] .
Until recently, agents approved for the treatment of PAH all belong to the following major therapeutic classes, which target three major molecular pathways involved in PAH pathogenesis: the prostanoids (prostacyclin pathway), endothelin-1 receptor antagonists (endothelin-1 pathway), and phosphodiesterase type 5 inhibitors (nitric oxide pathway). An additional class of agent targeting the nitric oxide pathway became available with the approval of riociguat, a soluble guanylate cyclase stimulator. All three major molecular pathways regulate pulmonary vasomotor tone and are also involved (to a variable extent) in the control of vascular cell proliferation. In PAH, there is enhanced pulmonary vasoconstriction with smooth muscle hyperplasia and a pro-proliferative, anti-apoptotic phenotype of endothelial cells 14, 21 .
Current approach to management of pulmonary arterial hypertension
General measures include correction of hypoxaemia with supplemental oxygen, diuretics for control of volume status, exercise rehabilitation, avoidance of pregnancy in women of childbearing age, and psychological support 1 . Anticoagulation should be considered for patients with idiopathic, heritable, or drug-induced PAH, although evidence supporting this practice is derived mainly from retrospective studies or single-centre experience 22, 23 .
However, a recent analysis of the large US Registry to Evaluate Early and Long-Term Disease Management in PAH (REVEAL) did not demonstrate any survival benefit for patients with idiopathic PAH who were initiated on warfarin 24 . The role of anticoagulation for other forms of PAH is even less clear 24, 25 , particularly in the setting of systemic sclerosis where increased risk of gastrointestinal bleeding requires careful consideration.
The approach to PAH therapy has undergone significant evolution since intravenous epoprostenol was first approved by the FDA in 1997. Table 2 summarises the different PAH agents according to their mechanism of action. With different classes of agents becoming available, there has been a major shift away from the sole use of monotherapy towards combination right ventricular function. Table 3 provides the current ESC/ERS recommendations on risk assessment in PAH.
Patients with high-risk features should be offered aggressive upfront combination therapy at the time of diagnosis, and one of the agents included should be intravenous epoprostenol 1 . Despite the complexities of continuous intravenous therapy, epoprostenol remains the only agent that has demonstrated a survival benefit over three months in high-risk patients 29 . Thus, intravenous epoprostenol should be viewed as the cornerstone of PAH therapy in those with severe, high-risk disease. Recently, Sitbon et al. 30 showed major functional and haemodynamic improvements in a group of high-risk patients with idiopathic, heritable, or anorexigen-induced PAH who were initiated on upfront triple therapy with intravenous epoprostenol, bosentan, and sildenafil. Patients were in FC III-IV at presentation, with severe haemodynamic impairment (defined as < 2.0 l·min −1 ·m −2 and/or mean right atrial pressure > 20 mmHg and/ or PVR ≥ 1000 dyn·s·cm −5 ). At an average follow-up of 32.3 ± 19.4 months, 17 of 19 patients were maintained in FC I-II, six-minute walk distance (6-MWD) improved from a baseline of 227 ± 171 to 514 ± 105 m (p < 0.01), and survival was 100% with only one patient requiring lung transplantation. Although this series was small and observational in nature, it provides support for the strategy of combining intravenous epoprostenol with oral agents as initial therapy for high-risk PAH. An important aspect of the current approach to PAH therapy is that patients should be monitored closely with early assessment (3-4 months) of treatment response following initiation of first-line therapy, regardless of whether an upfront monotherapy or combination therapy strategy is adopted. The goal of therapy is to achieve and maintain a lowrisk profile, according to the risk assessment described above ( In terms of upfront combination therapy, only two RCTs have been published to date. As discussed earlier, the AMBITION study 31 demonstrated that the combination of ambrisentan and tadalafil was superior to monotherapy alone in the first event of clinical failure. Although treatment was well tolerated in general, (Table 3) . ‡ Initial combination with ambrisentan and tadalafil has proven to be superior to initial monotherapy with either ambrisentan or tadalafil in delaying clinical failure. § Intravenous epoprostenol should be prioritised as it has reduced the three months rate for mortality in high-risk PAH patients also as monotherapy. ¶ Combine agents acting on different pathomechanistic pathways ( adverse events that occurred more frequently in the ambrisentan/tadalafil combination group included peripheral oedema, headache, nasal congestion, and anaemia. BREATHE-2 34 was a small study of 33 PAH patients who were randomised to upfront combination therapy with epoprostenol plus bosentan or epoprostenol alone. The primary endpoint of haemodynamic improvement was not met, although there was a trend towards a greater reduction in PVR in the combination therapy group. No significant differences in FC or 6-MWD were observed, although this study was not powered to address these clinical endpoints.
A larger number of RCTs are available with regards to sequential combination therapy in PAH. However, results have been mixed, with some trials failing to meet their primary endpoint (Table 4 ).
The PACES trial 35 (Pulmonary Arterial hypertension Combination study of Epoprostenol and Sildenafil) evaluated the addition of sildenafil to background intravenous epoprostenol therapy. After 16 weeks of treatment, improvements were seen in haemodynamics, 6-MWD, and time to clinical worsening compared with placebo. However, the sequence of adding sildenafil on top of background intravenous epoprostenol therapy is not commonly employed in clinical practice, particularly in view of the current recommendation that high-risk patients should be initiated on upfront combination therapy with intravenous epoprostenol being one of the agents.
The addition of macitentan to background PAH therapy in the SERAPHIN trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was demonstrated to be effective in a long-term morbidity/mortality event-driven study 36 . In this study, a total of 742 patients were randomised to macitentan versus placebo, with 454 patients on existing phosphodiesterase type 5 (PDE-5) inhibitor and 40 patients on non-parenteral prostanoid therapies. Macitentan at 10 mg was associated with a reduction in hazard ratio versus placebo of 0.55 (97.5% CI: 0.39-0.76; p = < 0.001) for the primary composite morbidity/mortality endpoint, which was mainly driven by worsening of PAH.
Riociguat is a soluble guanylate cyclase stimulator acting on the nitric oxide pathway, and is efficacious when combined with endothelin-1 receptor antagonists (ERA) and non-parenteral prostanoids (PATENT-1: Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1) 37 . The traditional endpoint of 6-MWD was used in this RCT and 222 of 443 patients were on background therapy with predominantly ERAs (n = 194). Addition of riociguat to background therapy at 12 weeks led to significant improvements in 6-MWD, PVR, NT-proBNP, FC, and time to clinical worsening.
The combination of riociguat added to PDE-5 inhibitors is contraindicated. In the small PATENT-PLUS study 38 (n = 18), combination therapy (riociguat added to sildenafil) demonstrated no beneficial effects at 12 weeks in terms of haemodyamics and 6-MWD. The primary outcome was a safety endpoint of supine systolic blood pressure, which did not show any difference between riociguat and placebo. In the long-term open-label extension study, the combination of riociguat and sildenafil was associated with unfavourable safety signals, with high rates of discontinuation due to hypotension and adverse events.
Despite the widespread use of the bosentan and sildenafil combination, the efficacy of this combination has not been proven in the setting of RCTs. The COMPASS-2 study 39 was a phase IV RCT, which evaluated the addition of bosentan to patients on background sildenafil therapy. Overall, 334 patients were randomised to bosentan or placebo and the composite primary endpoint of time to the first morbidity/mortality event was not met (defined as death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or worsening PAH). However, significant improvements were seen in the secondary endpoints of 6-MWD and NT-proBNP. A smaller study that evaluated the opposite approach of adding sildenafil to background bosentan therapy did not meet its primary endpoint of 6-MWD (NCT00323297) 40 .
Upcoming therapies in pulmonary arterial hypertension
Selexipag is a highly selective agonist of the IP receptor, the main target of the prostacyclin pathway 41, 42 . It is a novel agent that is given orally and is distinct in terms of its molecular structure from currently approved prostacyclin derivatives. Selexipag was recently tested in the largest RCT in PAH to date (GRIPHON trial: Prostacyclin (PGI2) Receptor agonist In Pulmonary arterial HypertensiON) 43 , which enrolled 1,156 patients with PAH. The majority of patients (80%) were on background therapy with either endothelin receptor antagonist (ERA) or PDE-5 inhibitor monotherapy (47%), or ERA plus PDE-5 inhibitor dual combination therapy (33%). Importantly, GRIPHON represents the first trial where a substantial subgroup was on dual background therapy. The primary endpoint of time to first morbidity and mortality event was met for the overall study population, with hazard ratio of 0.60 (99% CI: 0.46-0.78; p < 0.0001) favouring selexipag-treated patients compared to placebo. Comparable benefits were also shown in those on dual background therapy. Selexipag appeared to be well tolerated and no new safety concerns were noted over the long-term administration of treatment.
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subgroup of precapillary pulmonary hypertension caused by persisting obstruction of the pulmonary arteries after pulmonary embolism despite three months of correct therapeutic anticoagulation 44 . Approximately 75% of patients will have antecedent symptomatic pulmonary embolism, but a significant proportion will not have a clear history 45 . CTEPH is likely to be under-diagnosed, and the true incidence and prevalence of the condition is uncertain. In recent studies which utilised right heart catheter for diagnosis, prevalence after acute pulmonary embolism has been estimated at 0.4-4.8% before two years [46] [47] [48] [49] .
The pathogenesis of CTEPH involves defective thrombus resolution with maladaptive vascular remodelling, leading to formation of organised fibrotic tissue and intraluminal webs and bands, which cause obstruction in the major pulmonary arteries 50 . Large vessel occlusion can be accompanied by a small vessel arteriopathy that is histologically similar to PAH 51 . This microvascular disease can be demonstrated in small vessels distal to both obstructed and non-obstructed elastic pulmonary arteries.
Chronic thromboembolic pulmonary hypertension is usually suspected by the presence of mismatched perfusion defects on ventilation-perfusion scintigraphy, which remains the most sensitive initial screening test 52 . The diagnosis of CTEPH is confirmed by subsequent demonstration of obstruction of the pulmonary arteries on imaging modalities such as conventional digital subtraction pulmonary angiography or computed tomography pulmonary angiography. Invasive haemodynamic testing is required to confirm the presence of precapillary PH. Lifelong anticoagulation (usually with warfarin) is mandatory for patients with CTEPH and data is currently lacking to support the use of novel oral anticoagulants in this population 53, 54 .
Surgical therapy
Pulmonary endarterectomy (PEA) remains the treatment of choice for CTEPH and is potentially curative. At high-volume centres, surgical results have improved substantially over time. Periprocedural mortality is < 5% due to greater surgical experience, improved patient selection, and postoperative care 55, 56 .
A multidisciplinary assessment of operability at a PEA centre by PH physicians, surgeons, and radiologists is mandatory since not all patients are deemed to be suitable for PEA based on the site of disease or severe medical comorbidities 1, 44 . The assessment of operability remains subjective and is largely dependent on the experience and surgical expertise of the centre. Thus, referral for a second opinion should be considered if the decision regarding operability is not straightforward 44 . Some patients will have predominantly distal disease that is regarded as technically inaccessible by the surgeon, or the burden of surgically accessible disease is inadequate to explain the severity of haemodynamic impairment, suggesting the presence of a major component of distal disease. Age in itself is not a contraindication, and there is no PVR threshold or degree of right ventricular dysfunction that necessarily precludes PEA 55 .
Warranting mention is the subset of patients with symptomatic chronic thromboembolic disease without resting PH. The approach to these patients is not standardised, but given the potential for progression of disease, PEA should be considered, especially in those who demonstrate abnormal cardiopulmonary response during exercise. A recent case series of PEA in 42 patients with chronic thromboembolic disease and mPAP < 25 mmHg demonstrated beneficial effects with improvements in exercise capacity and quality of life 57 .
According to European CTEPH registry data collected from 2007-2009, 37% of CTEPH patients were classified as inoperable, and 16.7% had persistent pulmonary hypertension postoperatively 58 . Patients should have comprehensive clinical re-evaluation following surgery to determine the haemodynamic result and whether significant persistent pulmonary hypertension is present. Regardless of surgical outcome, life-long anticoagulation must be continued.
Targeted medical therapy for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension
Given the similarities in the microvascular disease of PAH and CTEPH, targeted medical therapies have been evaluated to treat inoperable or recurrent/persistent CTEPH patients (Table 5) . Riociguat is the only drug currently approved for the treatment of inoperable CTEPH or persistent/recurrent CTEPH post-surgery. In CHEST-1 (CHronic thromboEmbolic pulmonary hypertension Soluble guanylate cyclase-stimulator Trial) 59 , a randomized, double-blind, placebo-controlled trial conducted in 261 patients with inoperable or persistent/recurrent CTEPH, riociguat significantly improved PVR, 6-MWD, FC, and NT-proBNP after 16 weeks of treatment and was generally well-tolerated. Importantly, all patients in CHEST-1 were assessed by an independent adjudication panel for the assessment of inoperability. The CHEST-2 60 open-label extension study showed sustained benefits in 6-MWD and FC for up to one year, with no new safety signals identified.
Sildenafil has been evaluated in a small RCT involving 19 patients with inoperable CTEPH 61 .
The primary endpoint of 6-MWD was negative, but a significant improvement in PVR was demonstrated in the sildenafil arm. The BENEFIT study (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension) 62 randomised 157 patients with inoperable CTEPH or persistent/ recurrent CTEPH post-surgery to bosentan or placebo. In this study, PVR and 6-MWD were used as co-primary endpoints, and a significant improvement in PVR but not 6-MWD was demonstrated in those assigned to bosentan. On-going RCTs are being conducted to evaluate the efficacy of subcutaneous treprostinil (NCT01416636) and macitentan (NCT02021292) for inoperable CTEPH.
Controlled data regarding preoperative treatment of CTEPH with medical therapies is lacking. The use of such "bridging" therapy prior to surgery in otherwise stable patients is not supported by current evidence and may delay appropriate surgery.
Balloon pulmonary angioplasty
Balloon pulmonary angioplasty (BPA) is a catheter-based technique that is garnering attention worldwide as a treatment option for inoperable CTEPH. The concept is simple and involves a balloon dilatation of occluded arteries 63 . Japanese investigators have refined the BPA technique in recent years, using smaller balloons and performing staged angioplasty procedures in an attempt to reduce the incidence of reperfusion pulmonary oedema and vascular injury 64 . Most patients require between 3-5 staged procedures in total in order to treat as many occluded arterial segments as possible.
Currently, BPA is being offered to suitable CTEPH patients who are inoperable (or have failed PEA) and have no contraindications to angioplasty such as advanced renal insufficiency. However, as surgical assessment of operability varies according to the experience of different centres, published data on BPA outcomes have included patients who might otherwise be deemed to be operable in other centres. Nevertheless, contemporary BPA studies [64] [65] [66] [67] [68] [69] show consistently favourable haemodynamic effects, reporting a 33-65% reduction in PVR, and improvements in FC and 6-MWD. Dramatic responses to BPA with normalisation or near-normalisation of haemodynamics have been reported. Regarding adverse events, recent studies [64] [65] [66] [67] [68] [69] report serious reperfusion pulmonary oedema in 0-7% of treated patients, pulmonary artery injury in 2-7% of patients, and periprocedural mortality of 0-10%. Long-term data regarding BPA outcomes are still lacking, although experience from Japanese investigators indicate that restenosis appears to be an uncommon event.
Although it is clear that BPA will play an important role in the management of CTEPH, its exact place in the treatment algorithm is still evolving. Further studies are required to determine whether BPA should be the initial treatment approach for suitable patients with inoperable CTEPH, or whether BPA can potentially be combined with surgery or even used in place of surgery in selected patients.
CONCLUSIONS
Significant developments in the treatment options for patients with PAH and CTEPH have occurred recently. The pathobiology of PAH is complex and involves multiple molecular pathways, some of which can now be targeted by an increasing number of approved agents. The PAH agents from different classes can be combined to maximise treatment response, and an aggressive upfront combination strategy should be employed particularly in patients who present with high-risk disease. Direct comparative data regarding the efficacy of different combinations of PAH agents are currently lacking. The cornerstone of CTEPH management requires a multidisciplinary team assessment to determine whether a patient has operable disease, since PEA is a potentially curative procedure. For inoperable CTEPH, riociguat has recently been approved and there is growing evidence in support of BPA, although extensive experience with this procedure remains limited outside of Japan. Whilst there is regional variation in access to subsidised therapy and technical expertise, it is exciting to see that the management options and outcomes for patients with PAH and CTEPH are continuing to improve over time.
